Prophylactic Administration of Natural Progesterone in the Prevention of Preterm Delivery in Twin Pregnancies

NCT ID: NCT01031017

Last Updated: 2014-12-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 390 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-06-30
• Study Completion Date: 2014-06-30

Brief Summary

Twin pregnancies are at substantial increased risk of preterm delivery. Prophylactic administration of progesterone in singleton pregnancies at risk of preterm delivery has been shown to be effective in reducing the rate of such complication. The aim of this study is to investigate the effect of prophylactic administration of natural progesterone in twin pregnancies on the rate of preterm births.

Detailed Description

In a double-blind, placebo controlled study performed in our Institution, Fonseca et al., investigated the use of micronized natural progesterone, crafted in vaginal capsules of 100mg, for the prevention of preterm delivery. The study involved 142 singleton pregnancies at high risk for premature birth (previous premature birth, cerclage and uterine malformation). The progesterone was introduced from 24 weeks to 34 weeks gestation. The authors observed a significant reduction of premature birth before 37 weeks (28,1% within the placebo group versus 13,8% within the treated group) and below 34 weeks (18,6% within the placebo group versus 2,8% within the treated group). Also, it was observed a reduction in the frequency of the uterine contractions in the progesterone group.

In the only study performed specifically among twin pregnancies, Anna Lisa et al. in 1980, administrated 250mg of 17αOH-PC or placebo (still oil) weekly, in 70 pregnant women with twin pregnancies, beginning before 28 weeks and continuing up to 37 weeks gestation. Seric levels of progesterone, estradiol, estriol, testosterone, and placental lactogenic hormone were also measured weekly. The differences among the achieved results within both groups, according the average in pregnancy duration (36,9 within the treated group, versus 37,3 within the placebo group), the average birthweight and the perimortality rate were not significantly different, as well as the levels of progesterone, estriol, estradiol, testosterone and placental lactogenic hormone. Nevertheless, this study was criticized for starting the use of progesterone at a late stage of pregnancy, in a considerable number of cases.

These studies suggest that in singleton pregnancies with a previous history of preterm birth progesterone treatment may prevent the patients from having subsequent premature births. Nonetheless, the results of these series must not be generalized to all pregnancies at high risk. Additional studies to evaluate the use of progesterone ovules in multiple pregnancies are necessary, as these pregnancies are increasing due to the advanced maternal age at the conception time and also due to the widespread use of assisted reproductive techniques.

Conditions

Preterm Delivery

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

placebo

group taking placebo

Group Type: PLACEBO_COMPARATOR

placebo

Intervention Type: DRUG

placebo

study group

group taking progesterone

Group Type: ACTIVE_COMPARATOR

progesterone

Intervention Type: DRUG

ovules, 200mg per vagina, once a day from 18 weeks

Interventions

progesterone

ovules, 200mg per vagina, once a day from 18 weeks

Intervention Type: DRUG

placebo

placebo

Intervention Type: DRUG

Other Intervention Names

utrogestan

Eligibility Criteria

Inclusion Criteria

• Naturally conceived diamniotic twin pregnancies.
• Absence of major fetal abnormalities (such as neural tube defects, abdominal wall defects, cardiac defects, hydrocephalus, malformations that course with polyhydramnios) at the anomaly scan.
• Gestational age between 18 - 21+6weeks at the moment of randomization.
• Patients that are not allergic to the progesterone capsule excipients (arachis oil, soy and lecithin).
• Patients who do not use other medicines that can alter the progesterone effects, such as: barbituric, carbamazepine, hydantoin, rifampicin, betablockers, teofiline or ciclosporin.
• Porphyria, otoscleroses, malignant disease or severe depressive state.

Exclusion Criteria

• Premature rupture of membranes diagnosed at the moment of recruitment.
• Subsequent diagnosis of major fetal abnormalities.
• Twin to twin transfusion syndrome diagnosed during the course of the pregnancy.
• Presence of ovular infection.
• Death of one or both fetuses in any time of the pregnancy.
• Giving up or discontinuing the use of the medication.
• Elective or iatrogenic premature birth (before 34 weeks).
• Present or past history of thromboembolic disease
• Uterine malformation
• Known or suspected breast or genitals malignancy tumor
• Plan to move to another city during pregnancy
• Placenta Previa

• Minimum Eligible Age: 15 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

University of Sao Paulo

OTHER

Sponsor Role: lead

Responsible Party

Maria de Lourdes Brizot

PhD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Maria Brizot, PhD

Role: PRINCIPAL_INVESTIGATOR

Department of Obstetrics, São Paulo University Medical School

Locations

Hospital das Clinicas

São Paulo, São Paulo, Brazil

Countries

Brazil

Other Identifiers

418/04

Identifier Type: -

Identifier Source: org_study_id